title: Single dose treatment of malaria - current status and perspectives.
abstract: Despite increased international efforts for control and ultimate elimination, malaria remains a major health problem. Currently, artemisinin-based combination therapies are the treatment of choice for uncomplicated malaria exhibiting high efficacy in clinical trial settings in sub-Saharan Africa. However, their administration over a three-day period is associated with important problems of treatment adherence resulting in markedly reduced effectiveness of currently recommended antimalarials under real world settings.
  
  
  
  Antimalarial drug candidates and antimalarial drug combinations currently under advanced clinical development for the indication as single dose antimalarial therapy. Expert commentary: Several new drug candidates and combinations are currently undergoing pivotal proof-of-concept studies or clinical development programmes. The development of a single dose combination therapy would constitute a breakthrough in the control of malaria. Such an innovative treatment approach would simultaneously close the effectiveness gap of current three-day therapies and revolutionize population based interventions in the context of malaria elimination campaigns.
authors.affiliation: a Centre de Recherches Médicales de Lambaréné , Lambaréné , Gabon.|b Institut für Tropenmedizin , Universität Tübingen , Tübingen , Germany.
authors.forename: Johannes
authors.initials: J
authors.lastname: Mischlinger
authors.affiliation: a Centre de Recherches Médicales de Lambaréné , Lambaréné , Gabon.|b Institut für Tropenmedizin , Universität Tübingen , Tübingen , Germany.
authors.forename: Selidji T
authors.initials: ST
authors.lastname: Agnandji
authors.affiliation: a Centre de Recherches Médicales de Lambaréné , Lambaréné , Gabon.|b Institut für Tropenmedizin , Universität Tübingen , Tübingen , Germany.|c Department of Medicine I, Division of Infectious Diseases and Tropical Medicine , Medical University of Vienna , Vienna , Austria.
authors.forename: Michael
authors.initials: M
authors.lastname: Ramharter
mesh_terms: D000962:Antimalarials / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004338:Drug Combinations; D006801:Humans; D008288:Malaria / Q000188:drug therapy* / Q000453:epidemiology* / Q000469:parasitology / Q000517:prevention & control; D055118:Medication Adherence; D016896:Treatment Outcome
chemical_list: D000962:Antimalarials; D004338:Drug Combinations
keywords: AQ-13; DSM265; KAE609; KAF156; OZ277; OZ439; Single dose treatment; effectiveness; falciparum; ferroquine; malaria; naphthoquine; piperaquine; tafenoquine